Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application

Xia, Qing; Zhang, Yongtai; Li, Zhe; Hou, Xuefeng; Feng, Nianping

doi:10.1016/j.apsb.2019.01.011

Cited by 467 publications

(296 citation statements)

References 139 publications

(161 reference statements)

Supporting

Mentioning

291

Contrasting

Unclassified

Order By: Relevance

“…This membrane extraction procedure requires large volumes of cells to be harvested from culture dishes or blood and tissue samples [8,22,31,48,49]. This process has been accomplished in many ways including freeze-thaw cycling [36,48,50], electroporation [51], and osmosis-based lysis coupled with physical homogenization [22,48] ( Figure 3A). For freeze-thaw techniques, cells are frozen at −80 • C and thawed at either room temperature or 37 • C in repeated cycles.…”

Section: Membrane Extractionmentioning

confidence: 99%

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Harris

Scully

Day

2019

Cancers

188

125

View full text Add to dashboard Cite

Cancer is a global health problem in need of transformative treatment solutions for improved patient outcomes. Many conventional treatments prove ineffective and produce undesirable side effects because they are incapable of targeting only cancer cells within tumors and metastases post administration. There is a desperate need for targeted therapies that can maximize treatment success and minimize toxicity. Nanoparticles (NPs) with tunable physicochemical properties have potential to meet the need for high precision cancer therapies. At the forefront of nanomedicine is biomimetic nanotechnology, which hides NPs from the immune system and provides superior targeting capabilities by cloaking NPs in cell-derived membranes. Cancer cell membranes expressing "markers of self" and "self-recognition molecules" can be removed from cancer cells and wrapped around a variety of NPs, providing homotypic targeting and circumventing the challenge of synthetically replicating natural cell surfaces. Compared to unwrapped NPs, cancer cell membrane-wrapped NPs (CCNPs) provide reduced accumulation in healthy tissues and higher accumulation in tumors and metastases. The unique biointerfacing capabilities of CCNPs enable their use as targeted nanovehicles for enhanced drug delivery, localized phototherapy, intensified imaging, or more potent immunotherapy. This review summarizes the state-of-the-art in CCNP technology and provides insight to the path forward for clinical implementation.

show abstract

Section: Membrane Extractionmentioning

confidence: 99%

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Harris

Scully

Day

2019

Cancers

188

125

View full text Add to dashboard Cite

show abstract

“…In this case, the encapsulation of nanoparticles into RBCs creates a "camouflage" for them against the immune system [151]. One review [152] described, in detail, the types of nanoparticles that were already associated with the surface or loaded inside RBCs, as well as the prospects for their use in antitumor therapy.…”

Section: Nanoparticles and Erythrocytesmentioning

confidence: 99%

Erythrocytes as Carriers: From Drug Delivery to Biosensors

et al. 2020

View full text Add to dashboard Cite

Drug delivery using natural biological carriers, especially erythrocytes, is a rapidly developing field. Such erythrocytes can act as carriers that prolong the drug's action due to its gradual release from the carrier; as bioreactors with encapsulated enzymes performing the necessary reactions, while remaining inaccessible to the immune system and plasma proteases; or as a tool for targeted drug delivery to target organs, primarily to cells of the reticuloendothelial system, liver and spleen. To date, erythrocytes have been studied as carriers for a wide range of drugs, such as enzymes, antibiotics, anti-inflammatory, antiviral drugs, etc., and for diagnostic purposes (e.g., magnetic resonance imaging). The review focuses only on drugs loaded inside erythrocytes, defines the main lines of research for erythrocytes with bioactive substances, as well as the advantages and limitations of their application. Particular attention is paid to in vivo studies, opening-up the potential for the clinical use of drugs encapsulated into erythrocytes.Pharmaceutics 2020, 12, 276 2 of 44 property of RBCs allows to load them with biologically active substances of different molecular weights. For these reasons, erythrocytes are promising biocompatible cells for drug delivery.The methods for incorporating various substances into red blood cells differ in the way that substances penetrate the cells. The cause of permeability may be the pores' formation in the cell membrane due to a physical exposure (high voltage electric pulse [10,11] or ultrasound [12]). Drug molecules can also enter the RBCs by endocytosis in the presence of certain chemical compounds (for example, primaquine [13], vinblastine, chlorpromazine, hydrocortisone or tetracaine [14,15]), or using the cell-penetrating peptides bounded to the compound that should be encapsulated [16]. However, the most popular are different variants of osmotic methods.In some cases, RBCs are first exposed to a hyperosmotic pulse of a low molecular weight substance that penetrates very well through the cell membrane (for example, dimethyl sulfoxide (DMSO) [17,18] or glucose [19,20]). After washing the cells, which decreases the external concentration of these compounds and creates a gradient of their concentration between both sides of the RBC membrane, the target drug is introduced into the external volume. Water with this drug begins to enter into the cells to decrease the osmotic pressure there. The process ends when the gradient of DMSO or glucose disappears. The pores close and part of the drug remains into RBCs. Other, the most popular of the osmotic methods are hypoosmotic. These methods are based on creating a hypotonic environment around RBCs, which causes swelling of the cells and opening pores in the cellular membrane, through which therapeutic compounds can penetrate RBCs. Then, a hypertonic solution is introduced into the cell suspension. The pores close, the cells restore their original size, trapping the drug molecules inside the cell. Osmotic methods are divided into severa...

show abstract

“…This corresponds to greatly improved circulation times, which can reach up to 120 days. Xia et al reported on a number of developments in this arena where patient-specific RBC character can be mapped onto the RBCM-NP theranostic agents (111). Further preclinical testing of such novel theranostic nanoagents for US and PA image-guided PDT is currently underway by several groups.…”

Section: Enhancing Oxygen Content In the Microenvironment Via Nanoagentsmentioning

confidence: 99%

Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer

Hester

Kuriakose

Nguyen

et al. 2020

Photochem & Photobiology

View full text Add to dashboard Cite

Photodynamic therapy (PDT) is a phototoxic treatment with high spatial and temporal control and has shown tremendous promise in the management of cancer due to its high efficacy and minimal side effects. PDT efficacy is dictated by a complex relationship between dosimetry parameters such as the concentration of the photosensitizer at the tumor site, its spatial localization (intracellular or extracellular), light dose and distribution, oxygen distribution and concentration, and the heterogeneity of the inter‐ and intratumoral microenvironment. Studying and characterizing these parameters, along with monitoring tumor heterogeneity pre‐ and post‐PDT, provides essential data for predicting therapeutic response and the design of subsequent therapies. In this review, we elucidate the role of ultrasound (US) and photoacoustic imaging in improving PDT‐mediated outcomes in cancer—from tracking photosensitizer uptake and vascular destruction, to measuring oxygenation dynamics and the overall evaluation of tumor responses. We also present recent advances in multifunctional theranostic nanomaterials that can improve either US or photoacoustic imaging contrast, as well as deliver photosensitizers specifically to tumors. Given the wide availability, low‐cost, portability and nonionizing nature of US and photoacoustic imaging, together with their capabilities of providing multiparametric morphological and functional information, these technologies are thusly inimitable when deployed in conjunction with PDT.

show abstract

Red blood cell membrane-camouflaged nanoparticles: a novel drug delivery system for antitumor application

Cited by 467 publications

References 139 publications

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Cancer Cell Membrane-Coated Nanoparticles for Cancer Management

Erythrocytes as Carriers: From Drug Delivery to Biosensors

Role of Ultrasound and Photoacoustic Imaging in Photodynamic Therapy for Cancer

Contact Info

Product

Resources

About